New strategy aims to stop blood Cancer's return after transplant
NCT ID NCT04742634
Summary
This study is testing a new approach for patients with myelodysplastic syndromes (MDS, a type of blood cancer) who have had a stem cell transplant. Researchers will use a sensitive blood test one month after transplant to check for tiny traces of leftover cancer. If found, patients will receive a two-drug treatment (DEC-C) early, with the goal of stopping the cancer from coming back and improving survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.